INTEGRA LIFESCIENCES HOLDINGS CORP IART
INTEGRA LIFESCIENCES HOLDINGS CORP (IART) earns a Piotroski F-score of 5/9 (mixed financial health), with an Altman Z″ in the grey zone. It does not currently pay a dividend. FY2025 revenue was $1.6B at a -31.6% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Beneish M-score: -3.24 — low (below −2.22 — no manipulation red flag) . A statistical screen for earnings manipulation, not proof — and it doesn't apply to most banks/insurers.
Analyst price target
Wall Street analyst consensus — a sentiment gauge, not our scoring.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 5/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · grey zone
| Component | Value |
|---|---|
| Working capital / assets | 0.195 |
| Retained earnings / assets | 0.118 |
| EBIT / assets | -0.137 |
| Equity / liabilities | 0.408 |
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| IART | INTEGRA LIFESCIENCES HOLDINGS CORP | 5/9 | 1.17 | — | +1.5% |
| MMSI | MERIT MEDICAL SYSTEMS INC | 7/9 | 4.93 | 33.3 | +11.8% |
| PEN | Penumbra Inc | 6/9 | 8.59 | 70.1 | +17.5% |
| HAE | HAEMONETICS CORP | 7/9 | 2.85 | 36.1 | -2% |
| TFX | TELEFLEX INC | 5/9 | 3.56 | — | +17.2% |
| EMBC | Embecta Corp. | 6/9 | 1.99 | 2.2 | -3.8% |
| ICUI | ICU MEDICAL INC/DE | 6/9 | 2.9 | — | -6.3% |
About INTEGRA LIFESCIENCES HOLDINGS CORP
Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical, ear, nose, throat, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates through Codman Specialty Surgical and Tissue Technologies segments. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment. It also offers after-market services; surgical headlamps and instrumentation; instrument patterns and surgical and lighting products to hospitals, surgery centers, dental, podiatry, and veterinary offices. In addition, the company provides treatment of acute wounds, such as burns; chronic wounds, including diabetic foot ulcers; and surgical tissue repair applications, including hernia reinforcement, tendon protection, and peripheral nerve repair. Further, it offers skin and wound repair, plastics and surgical reconstruction products, and nerve and tendon repair products. Additionally, the company is involved in the ear, nose, and throat business that includes instrumentation, balloon technologies for sinus dilation and eustachian tube dilation, and surgical navigation systems. It offers its products directly through various salesforces and other distribution channels to the hospitals, integrated health networks, group purchasing organizations, clinicians, surgery centers, and health care providers in the United States, Europe, the Asia Pacific, and internationally. Integra LifeSciences Holdings Corporation was formerly known as Integra LifeSciences Corp. and changed its name to Integra LifeSciences Holdings Corporation in June 1995. Integra LifeSciences Holdings Corporation was incorporated in 1989 and is headquartered in Princeton, New Jersey.
FAQ
Is IART financially healthy?
INTEGRA LIFESCIENCES HOLDINGS CORP's Piotroski F-score is 5/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the grey zone.
Does IART pay a dividend?
No, INTEGRA LIFESCIENCES HOLDINGS CORP does not currently pay a dividend.
How profitable is IART?
In FY2025, INTEGRA LIFESCIENCES HOLDINGS CORP had a net margin of -31.6% and a return on equity of -49.5%.
Is IART overvalued or undervalued?
INTEGRA LIFESCIENCES HOLDINGS CORP trades at about 20.7× trailing earnings — below its 10-year norm (10-year range 26.5×–94.9×, median 47.8×). Stocktoria reports the data, not buy/sell advice.
What is the analyst price target for IART?
The average Wall-Street price target for INTEGRA LIFESCIENCES HOLDINGS CORP is $17.43, about 0.3% above the recent price, from 7 analysts (consensus: hold).
Is IART a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on INTEGRA LIFESCIENCES HOLDINGS CORP: a Piotroski F-score of 5/9, an Altman Z″ in the grey zone. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.